The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

Abstract The impact of different first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)s to the clinical efficacy of osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired T790M was still unclear. We enrolled 733 advanced EGFR-mutant NSCLC pa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4f433cf6fdce431dbf4471b897e379b4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4f433cf6fdce431dbf4471b897e379b4
record_format	dspace
spelling	oai:doaj.org-article:4f433cf6fdce431dbf4471b897e379b42021-12-02T17:47:23ZThe impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M10.1038/s41598-021-91657-72045-2322https://doaj.org/article/4f433cf6fdce431dbf4471b897e379b42021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91657-7https://doaj.org/toc/2045-2322Abstract The impact of different first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)s to the clinical efficacy of osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired T790M was still unclear. We enrolled 733 advanced EGFR-mutant NSCLC patients with gefitinib, erlotinib or afatinib as first-line EGFR-TKIs treatment for analysis. 373 patients received re-biopsies after progressive disease to first-line EGFR-TKIs treatment, and the total positive rate of T790M was 51.7%. 151 patients who harbored T790M received osimertinib as subsequent treatment. Among them, the median progression-free survival (PFS) of first-line EGFR-TKI (PFS1) was 14.0 months, and the median PFS of osimertinib (PFS2) was 10.1 months. The median PFS1 + PFS2 was 27.5 months, and the median overall survival from first-line EGFR-TKI was 61.3 months. Concerning different first-line EGFR-TKIs, the median PFS2 was 10.9 months in the gefitinib group, 10.0 months in the erlotinib group, and 6.7 months in the afatinib group (p = 0.534). The median PFS1 + PFS2 was 27.7 months, 26.8 months and 24.0 months in the gefitinib, erlotinib, and afatinib group, respectively (p = 0.575). In conclusion, both first-generation and second-generation EGFR-TKIs sequential osimertinib treatment provided good clinical efficacy in advanced EGFR-mutant NSCLC patients with acquired T790M mutation.Yen-Hsiang HuangJeng-Sen TsengKuo-Hsuan HsuKun-Chieh ChenKang-Yi SuSung-Liang YuJeremy J. W. ChenTsung-Ying YangGee-Chen ChangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yen-Hsiang Huang Jeng-Sen Tseng Kuo-Hsuan Hsu Kun-Chieh Chen Kang-Yi Su Sung-Liang Yu Jeremy J. W. Chen Tsung-Ying Yang Gee-Chen Chang The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
description	Abstract The impact of different first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)s to the clinical efficacy of osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired T790M was still unclear. We enrolled 733 advanced EGFR-mutant NSCLC patients with gefitinib, erlotinib or afatinib as first-line EGFR-TKIs treatment for analysis. 373 patients received re-biopsies after progressive disease to first-line EGFR-TKIs treatment, and the total positive rate of T790M was 51.7%. 151 patients who harbored T790M received osimertinib as subsequent treatment. Among them, the median progression-free survival (PFS) of first-line EGFR-TKI (PFS1) was 14.0 months, and the median PFS of osimertinib (PFS2) was 10.1 months. The median PFS1 + PFS2 was 27.5 months, and the median overall survival from first-line EGFR-TKI was 61.3 months. Concerning different first-line EGFR-TKIs, the median PFS2 was 10.9 months in the gefitinib group, 10.0 months in the erlotinib group, and 6.7 months in the afatinib group (p = 0.534). The median PFS1 + PFS2 was 27.7 months, 26.8 months and 24.0 months in the gefitinib, erlotinib, and afatinib group, respectively (p = 0.575). In conclusion, both first-generation and second-generation EGFR-TKIs sequential osimertinib treatment provided good clinical efficacy in advanced EGFR-mutant NSCLC patients with acquired T790M mutation.
format	article
author	Yen-Hsiang Huang Jeng-Sen Tseng Kuo-Hsuan Hsu Kun-Chieh Chen Kang-Yi Su Sung-Liang Yu Jeremy J. W. Chen Tsung-Ying Yang Gee-Chen Chang
author_facet	Yen-Hsiang Huang Jeng-Sen Tseng Kuo-Hsuan Hsu Kun-Chieh Chen Kang-Yi Su Sung-Liang Yu Jeremy J. W. Chen Tsung-Ying Yang Gee-Chen Chang
author_sort	Yen-Hsiang Huang
title	The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
title_short	The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
title_full	The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
title_fullStr	The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
title_full_unstemmed	The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
title_sort	impact of different first-line egfr-tkis on the clinical outcome of sequential osimertinib treatment in advanced nsclc with secondary t790m
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4f433cf6fdce431dbf4471b897e379b4
work_keys_str_mv	AT yenhsianghuang theimpactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT jengsentseng theimpactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT kuohsuanhsu theimpactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT kunchiehchen theimpactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT kangyisu theimpactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT sungliangyu theimpactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT jeremyjwchen theimpactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT tsungyingyang theimpactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT geechenchang theimpactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT yenhsianghuang impactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT jengsentseng impactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT kuohsuanhsu impactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT kunchiehchen impactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT kangyisu impactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT sungliangyu impactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT jeremyjwchen impactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT tsungyingyang impactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m AT geechenchang impactofdifferentfirstlineegfrtkisontheclinicaloutcomeofsequentialosimertinibtreatmentinadvancednsclcwithsecondaryt790m
_version_	1718379465865691136

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

Ejemplares similares